Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension
JAMA2023Vol. 330(12), pp. 1140–1140
Citations Over TimeTop 1% of 2023 papers
Luke J. Laffin, David Rodman, James M. Luther, Anand Vaidya, Matthew R. Weir, Natasa Rajicic, Brian Taylor Slingsby, Steven E. Nissen, Target-HTN Investigators, Richard Beasley, Matthew J. Budoff, George Carr, Michael P. Carroll, José Yépez, Anil Chhabra, Frank Cole, Leonard Dunn, William Eaves, Valentine M. Ebuh, Roger Estevez, Glenn Gould, Matthew Hong, Bruce Iteld, Mahendra Jain, Charles Kemp, C Kennelly, Mark Kleiner, Mark E Kutner, Luke J. Laffin, Joseph Lambert, Gilbert Ledesma, Keung Lee, John Lentz, Steven Lupovitch, James M. Luther, Lon Lynn, Obadias Marquez, Mobeen Mazhar, David P. Morin, Joel Neutel, Yaa Oppong, M Pan Alvarez Osorio, Andres Patron, Walter Pharr, Mercedes Ponce de Leon, Lilia Rodriguez-Ables, Jeffrey B. Rosen, Issac Sachmechi, Ronald Surowitz, Larkin T. Wadsworth, Jeffrey D. Wayne, Zahid N. Zafar
Abstract
ClinicalTrials.gov Identifier: NCT05001945.
Related Papers
- → Pathology and gene mutations of aldosterone-producing lesions(2023)8 cited
- → Associations between aldosterone synthase gene polymorphism and the adrenocortical function in males(1998)100 cited
- → Selective aldosterone synthase inhibitors reduce aldosterone formation in vitro and in vivo(2009)23 cited
- → Direct radioimmunoassays for "aldosterone" and "18-hydroxycorticosterone" in unprocessed urine, and their use in screening to distinguish primary aldosteronism from hypertension.(1982)18 cited
- Relationship of aldosterone synthase gene polymorphism with plasma aldosterone levels of essential hypertension patients(2004)